1. Home
  2. NUR vs BOLT Comparison

NUR vs BOLT Comparison

Compare NUR & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuran Wireless Inc. Common Shares

NUR

Nuran Wireless Inc. Common Shares

N/A

Current Price

$0.40

Market Cap

7.8M

Sector

N/A

ML Signal

N/A

Logo Bolt Biotherapeutics Inc.

BOLT

Bolt Biotherapeutics Inc.

N/A

Current Price

$6.11

Market Cap

7.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NUR
BOLT
Founded
N/A
2015
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.8M
7.7M
IPO Year
2016
2021

Fundamental Metrics

Financial Performance
Metric
NUR
BOLT
Price
$0.40
$6.11
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
★ $41.00
AVG Volume (30 Days)
446.6K
★ 692.8K
Earning Date
08-28-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $7,695,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 0.07
52 Week Low
$0.36
$5.89
52 Week High
$7.72
$14.40

Technical Indicators

Market Signals
Indicator
NUR
BOLT
Relative Strength Index (RSI) 25.39 39.42
Support Level $0.36 N/A
Resistance Level $0.83 $8.72
Average True Range (ATR) 0.09 0.40
MACD 0.00 -0.05
Stochastic Oscillator 8.97 22.94

Price Performance

Historical Comparison
NUR
BOLT

About NUR Nuran Wireless Inc. Common Shares

Nuran Wireless Inc is engaged in the Network as a Service (NAAS) business. The group operates in the research, development, manufacturing, marketing, and operation of digital electronic circuits and wireless telecommunication products and offers services in the mobile telephony industry. It also provides products and services that help mobile network operators profitably serve off-grid markets that are currently not served. It has two reportable segments: NaaS and Direct Sales. The majority of the revenue is derived from Africa.

About BOLT Bolt Biotherapeutics Inc.

Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.

Share on Social Networks: